Kiniksa Pharmaceuticals International, plc KNSA Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's operating income?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported operating income of $29.27M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's operating income changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's operating income increased by 120.5% year-over-year, from $13.27M to $29.27M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's operating income?
- Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's operating income has grown at a -16.2% compound annual growth rate (CAGR), from -$156.64M to $77.22M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.